CompletedPhase 3

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

60 participantsStarted 2001-10

Plain-language summary

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease Exclusion Criteria: * Patient cannot stand or sit upright for at least 30 minutes * Patient has difficulty swallowing or problems with digestive system

What they're measuring

Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months

Trial details

NCT IDNCT00480662

SponsorOrganon and Co

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2002-10

View on ClinicalTrials.gov More Paget's Disease of Bone trials